Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02939404
Other study ID # 999917004
Secondary ID 17-DK-N004
Status Recruiting
Phase
First received
Last updated
Start date April 27, 2017
Est. completion date December 31, 2024

Study information

Verified date December 18, 2023
Source National Institutes of Health Clinical Center (CC)
Contact Kat A Ware
Phone Not Listed
Email niddkphoenixcontact@mail.nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

One reason people gain weight is eating more calories from food than what they need for energy over 24 hours. Metabolism is the amount of energy a person uses over 24 hours. Researchers want to study the relationship between changes in metabolism and how much a person eats. Objectives: To see how much food a person eats when the body's temperature is cooled. To study how changes in metabolism may alter the amount of food a person eats. Eligibility: Healthy people ages 18-55. Design: Participants will stay at NIH for 20 days. During the first 4 days, participants will have: - Medical exam - Electrocardiogram - Blood and urine tests. One blood test includes drinking a sugar solution. - DXA body composition scan - Questions about foods they like, physical activity, and personal behavior - Exercise test on a stationary bicycle Participants will spend 24-hour periods in a metabolic chamber. The chamber will be at normal room temperature or cooler. Some times, participants will eat a diet that matches their daily needs. Other times, they can eat as much as they wish from a vending machine. Participants will have blood and urine collected. Participants will swallow an ingestible wireless sensor and wear a small data recorder device. On the second to last day, participants will stay in the metabolic chamber but only consume water and non-caffeinated sugar-free beverages. Participants will come back for 1-day visits at six months and one year from the first admission. They will have blood and urine tests, and a DXA scan. They will answer questions on physical activity and food habits.


Description:

More than 30% of adults are considered overweight. In general, lifestyle changes (diet and exercise) or current weight loss drugs only lead to about 5 to 10% weight loss. This may be because a person s energy expenditure, aka the number of calories the body uses, leads to hunger and may increase the amount of food a person eats. Cold exposure is known to increase metabolism but it may not lead to weight loss if appetite and the desire for food are also increased. The primary goal of this study is to evaluate whether changing energy expenditure by cool temperature exposure results in changes in food intake. This study will involve a stay on our clinical research unit where we will determine the energy requirements (at 24 degree C) of 68 healthy, adult volunteers without evidence of diabetes. Exposure to cool temperatures (16 degree C) will be used to increase the number of calories a person s body uses in a day. Participants will spend 24 hours in a room that measures energy expenditure while the temperature in the room is turned down, once with a fixed diet and once with a buffet of food choices. After the fixed diet, volunteers will self-select how much food they wish to eat for one day from a vending machine. Volunteers will also spend one day fasting followed by a day self-selecting their food from the vending machine. Findings from this study will provide knowledge about a possible causal link between energy expenditure and eating behavior. This information may shed light on why many weight loss interventions that increase energy expenditure do not work as well as expected, and may eventually lead to new weight loss approaches and therapies.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility - INCLUSION CRITERIA: - Premenopausal women and men <55 years of age - Body weight <204 kg (<450 pounds) and >= 36 kg (>= 80 pounds) - Stable weight (+/-5% within past 6 months) as determined by volunteer report - Healthy, as determined by medical history, physical examination, and laboratory tests EXCLUSION CRITERIA: - Age <18 years - Weight greater than or equal to 204 kg (greater than or equal to 450 pounds, maximum weight of the iDXA machine as per manufacturer s manual), or weight <36 kg (<80 pounds, minimum weight allowed based on the NIH guidelines of blood drawing for research purposes) - Use of medications affecting metabolism and appetite in the last three months - Expresses unwillingness to consume all food given during the weight maintaining diet portions of the study (e.g., due to strict dietary restrictions including allergies or vegetarian or kosher diet) - Current use of tobacco products, marijuana, amphetamines, cocaine, or intravenous drug use - Current pregnancy, pregnancy within the past 6 months or lactation - History or clinical manifestation of: - Type 1 and Type 2 diabetes mellitus - History of surgery for the treatment of obesity - Endocrine disorders, such as Cushing s disease, pituitary disorders, and hypo and hyperthyroidism - Pulmonary disorders, including chronic obstructive pulmonary disease - Cardiovascular diseases, including coronary heart disease, heart failure, arrhythmias, and peripheral artery disease - High blood pressure by sitting blood pressure measurement using an appropriate cuff higher than 140/90 mmHg on two or more occasions, or current antihypertensive therapy - Liver disease, including cirrhosis, active hepatitis B or C, and AST or ALT greater than or equal to 2x normal - Gastrointestinal disease including Crohn s disease, ulcerative colitis, celiac disease or other malabsorptive disorders - Abnormal kidney function (eGFR <60 mL/min/1.73m(2)) - Central nervous system disease, including previous history of cerebrovascular accidents, dementia, neurodegenerative disorders or history of severe head trauma - Cancer requiring treatment in the past five years, except for nonmelanoma skin cancers or cancers that have clearly been cured - Infectious disease such as active tuberculosis, HIV (by self report), chronic coccidiomycoses or other chronic infections that might influence EE and weight - Diagnosis of binge eating disorder, anorexia and major psychiatric disorders based upon the DSM-IV including depression, schizophrenia and psychosis, which may impact the ability of the participant to be in the respiratory chamber for 24 hour time periods - Chronic ethanol use (more than 3 drinks/day)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States NIDDK, Phoenix Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To investigate whether increases in EE lead to increased ad libitum food intake, as measured using a vending machine paradigm. metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 5, 6-9, 12, 13, 16, 19, 20
Primary To determine whether the effects of increased EE due to cool temperature exposure on energy intake are only concomitant with the increase in EE or persist until the following day. metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 5, 6-9, 12, 13, 16, 19, 20
Secondary To determine if any observed association between EE and energy intake predicts future weight change at 6 months and 1 year. weight; metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 1-20, 6 month and 1 year follow-up visits
Secondary To assess if concentrations of appetitive or exercise-induced hormones will correlate with the observed changes in EE and energy intake. blood and urine collection to determine biomarker concentrations; metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 5, 6, 9, 12, 13, 16, 19, 20
Secondary To assess whether the above behavioral testing as measured by previously validated questionnaires and tasks are associated with measured food intake or hormone concentrations. blood and urine collection to determine biomarker concentrations; metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 5, 6, 9, 12, 13, 16, 19, 20
Secondary To assess if behavioral testing addressing dietary restraint, stress related eating behaviors, and executive function or the responses to visual analogue scales assessing hunger modify any observed EE to energy intake association. questionnaires for food preferences, physical activity, dietary restraint, power of food, emotional overeating, frequency, stress, food security, anhedonia, and cognitive factors; metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 1-2, 5, 6-9, 12, 13, 16, 19, 20
Secondary To determine if the 24h EE responses to cool temperature exposure correlate with core body temperature or changes in peripheral skin temperatures, and to determine if these changes are related to body adiposity or associated with food intake. core body temperature; skin temperature; metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 5, 6-9, 12, 13, 16, 19, 20
Secondary To determine if the interventions will alter the 24h respiratory quotient (RQ, an approximation for the ratio of carbohydrate-to-fat oxidation rates), and test whether the induced RQ changes independently contribute to the altered energy intake. metabolic chamber to measure RQ and EE; vending machine paradigm to measure food intake Days 5, 9, 12, 16, 19
Secondary To determine whether 36 hrs of fasting will result in a change in energy intake on the following day, and to determine whether the decrease in 24h EE during fasting will correlate with amount of food consumed the following day. metabolic chamber to measure EE; vending machine paradigm to measure food intake Days 5, 6-9, 12, 13, 16, 19, 20
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1